Figure 5.

JAK-STAT signaling pathway activation promotes the osteogenic differentiation of LFCs. A, western blot analysis was performed to measure the phosphorylation of JAK2, STAT1 and STAT3 in LFCs; Then, OPLL-derived Fedratinib, a JAK2-specific agonist, was administrated into the LFCs; Next, B-C, the mRNA (b) and protein (c) expression of BMP2, RUNX2 and OCN was determined by QRT-PCR and western blot analysis, respectively; D-E, osteogenic properties of LFCs were detected by alizarin red staining (d) and ALP staining (e). The data are expressed as the mean ± SD; two-way ANOVA and Tukey’s multiple comparison test was used to determine statistical significance; *, p < 0.05